Coursera, Inc. (NYSE:COUR) is among the 15 Best Small Cap Stocks to Buy According to Wall Street. On February 9, 2026, JPMorgan lowered its price target on Coursera, Inc. (NYSE:COUR) to $10 from $12 ...

We believe Coursera (COUR) stock is worth considering: It is growing, generating cash, and offered at a substantial valuation discount. Companies like this can utilize cash to stimulate further ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The FDA has granted Cour Pharmaceuticals orphan drug ...

CHICAGO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- COUR Pharmaceuticals, a clinical-stage biotechnology company developing first-in-class, disease-modifying therapies designed to induce antigen-specific ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Local biotech startup Cour Pharmaceuticals has signed a ...

CHICAGO, Dec. 03, 2024 (GLOBE NEWSWIRE) -- COUR Pharmaceuticals, a clinical-stage biotechnology company developing first-in-class, disease-modifying therapies designed to induce antigen-specific ...

We recently published 10 Stocks Surprise Wall Street with Double-Digit Gains. Coursera, Inc. (NYSE:COUR) is one of the biggest performers recently. Coursera soared by 41.53 percent week-on-week, ...

COUR is trading near the bottom of its 52-week range and below its 200-day simple moving average. Price change The price of COUR shares has decreased $0.05 since the market last closed. This is a 0.82 ...

Cour Pharmaceuticals will change chief executives next month with founder, President and CEO John J. Puisis stepping aside for current Chief Operating Officer Dannielle Appelhans. The Chicago-based ...